Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT

Harding, Chris; Chadwick, Thomas; Homer, Tara; Lecouturier, Jan; Mossop, Helen; Carnell, Sonya; King, Will; Abouhajar, Alaa; Vale, Luke; Watson, Gillian; Forbes, Rebecca; Currer, Stephanie; Pickard, Robert; Eardley, Ian; Pearce, Ian; Thiruchelvam, Nikesh; Guerrero, Karen; Walton, Katherine; Hussain, Zahid; Lazarowicz, Henry; Ali, Ased

doi:10.3310/QOIZ6538

Graphic version of this page | Change how these pages look

Journals Library

NHS NIHR - National Institute for Health Research

Journals

Twitter
Facebook
LinkedIn
Email

An error occurred retrieving publication content to display, please try again.

Home >> Journals >> Health Technology Assessment >> Page Not Found

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Home >> Journals >> Health Technology Assessment >> Volume {{metadata.Volume}} >> Issue {{metadata.Issue}}
Extended Research Article
i

Toolkit

View Award

This trial showed that methenamine hippurate is not inferior to the current standard care of daily low-dose antibiotics in preventing recurrent urinary tract infections in women during 12 months of prophylactic treatment.

Detailed Author information
Detailed Author information

Chris Harding ^1,^2,^*, Thomas Chadwick ³, Tara Homer ³, Jan Lecouturier ³, Helen Mossop ³, Sonya Carnell ⁴, Will King ³, Alaa Abouhajar ⁴, Luke Vale ³, Gillian Watson ⁴, Rebecca Forbes ⁴, Stephanie Currer ⁴, Robert Pickard ^5,^†, Ian Eardley ⁶, Ian Pearce ⁷, Nikesh Thiruchelvam ⁸, Karen Guerrero ⁹, Katherine Walton ¹⁰, Zahid Hussain ¹¹, Henry Lazarowicz ¹², Ased Ali ¹³

¹ Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK
² Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
³ Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
⁴ Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
⁵ Institute of Cellular Medicine, The Medical School, Newcastle upon Tyne, UK
⁶ Leeds Teaching Hospitals NHS Trust, Leeds, UK
⁷ Manchester University NHS Foundation Trust, Manchester, UK
⁸ Addenbrooke’s Hospital, Cambridge, UK
⁹ Queen Elizabeth University Hospital, Glasgow, UK
¹⁰ Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, UK
¹¹ The Royal Oldham Hospital, Oldham, UK
¹² Liverpool University Hospitals NHS Foundation Trust, formerly The Royal Liverpool University Hospital, Liverpool, UK
¹³ Urology Department, Pinderfields Hospital, Wakefield, UK
^* Corresponding author Email: C.Harding@nhs.net

^† In memoriam

In memoriam

Declared competing interests of authors: Chris Harding reports personal fees from Astellas Pharma (Tokyo, Japan), Medtronic plc (Dublin, Ireland), Allergan Ltd (Dublin, Ireland), GlaxoSmithKline plc (Brentford, UK), Teleflex Medical Inc. (Temecula, CA, USA) and grants from Medtronic plc, the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme (HTA 15/40/05) and The Urology Foundation (London, UK) outside the submitted work. Karen Guerrero reports grants from the NIHR HTA programme (HTA 16/82/01 and HTA 15/150/05) and the NIHR Health and Social Care Delivery Research (HSDR) programme (HSDR 14/04/02), and a Contura International Ltd (London, UK) Departmental Education Grant to support national training courses to her department. Luke Vale reports being co-ordinating editor of Cochrane Incontinence (from 2016) and being a member of NIHR HTA, Clinical Evaluation and Trials Panel from 2015 to 2018. Thomas Chadwick reports grants from the NIHR HTA programme (HTA 16/154/01, HTA 15/130/94 and HTA 11/72/01) during the conduct of the study.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

[Image - Crossmark status check]

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

No responses have been published.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*
Name (title, first name, last name)*
Occupation / Job title*
Affiliation / Employer*
Email*
Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas
Statement of competing interestsWe believe that readers should be aware of any competing interests (conflicts of interest).The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.
If yes, please provide details below
Enter response title*
Enter CAPTCHA What is nine minus one?*

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document